WASHINGTON, D.C. – Today, AstraZeneca joined Boehringer Ingelheim as the second inhaler manufacturer to announce they are capping the out-of-pocket cost for their inhaler products at $35 per month in the United States. This news comes after Senator Baldwin and her colleagues launched an investigation into the high costs Americans pay for inhalers, demanding answers from the four biggest inhaler ma...
